WHO has issued two emergency use listings for Novavax’s COVID-19 vaccine following the publication of positive results from a phase 3 trial, and the company said it expects to begin submitting data to the FDA by the end of the year.
The first emergency use listing (EUL) was issued by WHO last week for the vaccine, named Covovax, that is produced by the Serum Institute of India under license
The World Health Organization (WHO) on Tuesday granted emergency use authorization to the Chinese Sinovac COVID-19 vaccine for people over the age of 18.
A survey of about 4,000 people by the federal Department of Health shows under half of those asked would get the vaccine as soon as it is available, but 71 per cent say they will choose to have the jab by October.